HOTH Stock Summary and Trading Ideas (Hoth Therapeutics | NASDAQ:HOTH)

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

Hoth Therapeutics trades on the NASDAQ stock market under the symbol HOTH.

As of December 24, 2025, HOTH stock price declined to $1.04 with 166,204 million shares trading.

HOTH has a beta of -0.01, meaning it tends to be less sensitive to market movements. HOTH has a correlation of 0.00 to the broad based SPY ETF.

HOTH has a market cap of $16.13 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, HOTH traded as high as $12.50 and as low as $.58.

The top ETF exchange traded funds that HOTH belongs to (by Net Assets): VXF.

HOTH has outperformed the market in the last year with a return of +27.2%, while the SPY ETF gained +17.3%. However, in the most recent history, HOTH shares have underperformed the stock market with its stock returning -49.8% in the last 3 month period and -12.6% for the last 2 week period, while SPY has returned +4.4% and +1.4%, respectively.

HOTH support price is $1.03 and resistance is $1.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HOTH shares will trade within this expected range on the day.